BioStock: Respiratorius and Iconovo collaborate on inhalation product for COPD

The two Lund-based development companies Respiratorius and Iconovo have signed an agreement to develop an inhalation formulation and an inhalation product of Respiratorius drug candidate RES030-085 for the treatment of COPD and severe asthma. A first inhalation product based on Iconovo's ICOone is intended to be used in a phase I clinical trial with the candidate. BioStock has spoken to the respective CEOs of the two companies to find out more about what this means.

Read the full article at biostock.se: 

https://www.biostock.se/en/respiratorius-and-iconovo-collaborate-on-inhalation-product-for-copd/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se